<DOC>
	<DOCNO>NCT00730158</DOCNO>
	<brief_summary>KD018 oral form spray dry aqueous extract compose four main herb , use Orient nearly 2000 year variety GI symptom include diarrhea nausea/vomiting . Extensive pre-clinical research do Chinese herbal medicine , study document significant anticancer activity combination various cytotoxic agent include Irinotecan , semi-synthetic derivative natural alkaloid camptothecin belongs class topoisomerase I inhibitor . The proposed plan investigate mechanism efficacy Chinese herbal medicine adjunct chemotherapy treatment patient metastatic colorectal cancer . Our rationale therapeutic use KD018 potential activity reduce chemotherapy-induced toxicity , especially diarrhea .</brief_summary>
	<brief_title>A Phase II Multicenter , Randomized , Placebo Controlled , Double Blinded Clinical Study KD018 Modulator Irinotecan Chemotherapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Patients histologically confirm metastatic colorectal cancer ( mCRC ) , receive and/or progress prior oxaliplatinbased chemotherapy regimen . 2 . Patients must chemotherapy least 4 week prior sign inform consent/start screening . 3 . Patients wildtype mutant KRAS mCRC . 4 . At least one measurable lesion RECIST 1.1 . 5 . ECOG PS Performance Status 02 . 6 . Must &gt; /=18 year age . 7 . Expected survival least 6 month . 8 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use acceptable contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) , must negative serum urine pregnancy test within 1 week prior begin treatment trial . Nursing patient exclude . Sexually active men must also use acceptable contraceptive method . Pregnant nursing patient exclude effect combination KD018 irinotecan fetus nursing child unknown . 9 . Must able willing give write informed consent . 10 . Patients must follow clinical laboratory value : 1 . ANC count &gt; /= 1,500/ mm3 . 2 . Platelets &gt; /= 100,000/ mm3 . 3 . Hemoglobin &gt; /= 9 gm/dL ( may correct transfusion ) . 11 . Evidence adequate hepatic function , Bilirubin &lt; 1.5 x upper limit normal ( ULN ) AST &lt; /= 2.5 x ULN ALT &lt; /= 2.5 x ULN ( Note , AST ALT do , must &lt; /= 2.5 x ULN ) OR AST &lt; /= 5.0 x ULN ALT &lt; /= 5.0 x ULN acceptable liver tumor involvement . ( Note , AST ALT do , must &lt; /= 5.0 x ULN ) 12 . Serum creatinine &lt; /=2 x ULN 13 . Serum potassium within institutional limit normal ( may correct potassium repletion ) . 1 . Continued treatment bevacizumab document evidence disease progression bevacizumabcontaining regimen . 2 . Uncontrolled symptomatic brain metastasis . 3 . Serious concomitant systemic disorder ( e.g. , active infection ) , opinion investigator , would compromise safety patient compromise patient 's ability complete study . 4 . Unwilling unable follow protocol requirement give informed consent . 5 . No treatment cytotoxic biologic agent within 4 week prior begin treatment study ( 6 week mitomycin nitrosoureas ) . At least 4 week must elapse prior surgery , radiation , hormonal drug therapy cancer . 6 . Known HIV positivity , safety patient population assess . 7 . Presence metastatic disease , opinion investigator , would require palliative treatment within 4 week enrollment . 8 . Altered mental status preclude understand informed consent process and/or completion necessary study . 9 . Pregnant breastfeed woman . 10 . Men woman childbearing age potential , willing use effective contraception . 11 . Major surgery within previous 4 week . 12 . Patients take concurrent medication kind strong inducer inhibitor CYP3A4 . 13 . Patients previously treat irinotecancontaining regimen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>